The Global Insulin Pumps Industry, with estimated revenues of US$ 5.5 billion in 2022, is set to experience remarkable growth at a CAGR of 10.3% from 2022 to 2032, according to a comprehensive report published by Future Market Insights (FMI). By the end of 2032, the market is anticipated to reach an impressive US$ 14.8 billion, marking a significant expansion in the industry.
The rising demand for tethered pumps is a key factor contributing to the industry’s growth, with projections indicating an absolute dollar opportunity of US$ 6.7 billion during the period 2022-2032.
A major driver behind this surge is the alarming increase in the incidence of diabetes, attributed to factors such as age, obesity, and an unhealthy lifestyle. The report highlights that obesity, a primary cause of diabetes, is leading to a rise in the prevalence of diabetes-related ocular illnesses. Shockingly, in 2017, global estimates revealed approximately 22.9 million new cases of diabetes, with a reported prevalence of around 476 million individuals. Tragically, 1.37 million fatalities were recorded due to diabetes, and 1.37 million disability-adjusted life-years (DALYs) were associated with this health challenge.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15803
Obesity and being overweight are risk factors that are increasing the occurrence of type II diabetes. As a result, risk factors such as smoking, being overweight, being obese, and having high cholesterol are likely to increase the prevalence of type II diabetes.
Global Insulin Pumps Industry Competitive Landscape
Over the projected period, rising emphasis on innovations and investments among public and private entities is expected to strengthen competition in the market. In addition, product commercialization and partnership tactics are expected to be profitable in the upcoming years.
The key vendors in the Global Insulin Pumps Industry are Cellenovo, Sooil Development, Valeritas, Inc, JingasuDelfu Co., Ltd., Medtronic plc, Hoffmann-La Roche Ltd, Tandem Diabetic Care, Inc., Insulet Corporation, and Ypsomed.
Some of the recent developments in the Global Insulin Pumps industry:
- In June 2019, Medtronic announced a partnership with Tidepool to develop an interoperable automated insulin pump system. The Medtronic MiniMed pump will serve as one of Tidepool Loop’s accessories, designed to communicate with Apple devices.
- In September 2020, Insulet Corporation, stated that its Omnipod DASH Insulin Management System would be widely available in Israel, Switzerland, Austria, Germany, Belgium, and France in the coming weeks. Denmark, Norway, Finland, and Sweden have already exposure to this product.
- In June 2020, Tandem Diabetes Care and Abbott announced a collaboration to develop and commercialize integrated diabetes care solutions. These products will combine Abbott’s continuous glucose monitoring technology with Tandem’s ground-breaking insulin delivery devices to better diabetic blood sugar control.
- In September 2020, Medtronic announced that their MiniMedTM 770G hybrid closed loop system has received FDA clearance in the United States. This unique insulin administration system, which is equipped with the company’s SmartGuard technology, and can be connected to a smartphone and can be modified for youngsters as young as two years old.
Request Methodology Now!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15803
Top 9 Key Companies Profiled in the Global Insulin Pumps Industry
- Medtronic plc
- Hoffmann-La Roche Ltd
- Tandem Diabetic Care, Inc.
- Insulet Corporation
- Ypsomed
- Cellenovo
- Sooil Development
- Valeritas, Inc
- JingasuDelfu Co., Ltd.
Market Segments Covered in Global Insulin Pumps Industry Analysis
By Type:
- Patch Pumps
- Tethered Pumps
By Product Type:
- Tandem
- Accu-Chek
- MiniMed
- Omnipod
- My Life Omnipod
- Other Product Types
By Accessories:
- Insulin reservoir or cartridges
- Insulin set insertion devices
- Battery
